These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 10665814)

  • 1. Determinants of voltage-dependent inactivation affect Mibefradil block of calcium channels.
    Jiménez C; Bourinet E; Leuranguer V; Richard S; Snutch TP; Nargeot J
    Neuropharmacology; 2000; 39(1):1-10. PubMed ID: 10665814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967).
    Bezprozvanny I; Tsien RW
    Mol Pharmacol; 1995 Sep; 48(3):540-9. PubMed ID: 7565636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. State-dependent inhibition of inactivation-deficient Ca(V)1.2 and Ca(V)2.3 channels by mibefradil.
    Bernatchez G; Sauvé R; Parent L
    J Membr Biol; 2001 Nov; 184(2):143-59. PubMed ID: 11719851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of voltage- and use-dependent block of class A Ca2+ channels by mibefradil.
    Aczél S; Kurka B; Hering S
    Br J Pharmacol; 1998 Oct; 125(3):447-54. PubMed ID: 9806326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-channel pharmacology of mibefradil in human native T-type and recombinant Ca(v)3.2 calcium channels.
    Michels G; Matthes J; Handrock R; Kuchinke U; Groner F; Cribbs LL; Pereverzev A; Schneider T; Perez-Reyes E; Herzig S
    Mol Pharmacol; 2002 Mar; 61(3):682-94. PubMed ID: 11854450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional expression of L- and T-type Ca2+ channels in murine HL-1 cells.
    Xia M; Salata JJ; Figueroa DJ; Lawlor AM; Liang HA; Liu Y; Connolly TM
    J Mol Cell Cardiol; 2004 Jan; 36(1):111-9. PubMed ID: 14734053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Actions of mibefradil, efonidipine and nifedipine block of recombinant T- and L-type Ca channels with distinct inhibitory mechanisms.
    Lee TS; Kaku T; Takebayashi S; Uchino T; Miyamoto S; Hadama T; Perez-Reyes E; Ono K
    Pharmacology; 2006; 78(1):11-20. PubMed ID: 16899990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High affinity interaction of mibefradil with voltage-gated calcium and sodium channels.
    Eller P; Berjukov S; Wanner S; Huber I; Hering S; Knaus HG; Toth G; Kimball SD; Striessnig J
    Br J Pharmacol; 2000 Jun; 130(3):669-77. PubMed ID: 10821797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of mibefradil on sodium and calcium currents.
    Strege PR; Bernard CE; Ou Y; Gibbons SJ; Farrugia G
    Am J Physiol Gastrointest Liver Physiol; 2005 Aug; 289(2):G249-53. PubMed ID: 15790762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mibefradil block of cloned T-type calcium channels.
    Martin RL; Lee JH; Cribbs LL; Perez-Reyes E; Hanck DA
    J Pharmacol Exp Ther; 2000 Oct; 295(1):302-8. PubMed ID: 10991994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. State-dependent mibefradil block of Na+ channels.
    McNulty MM; Hanck DA
    Mol Pharmacol; 2004 Dec; 66(6):1652-61. PubMed ID: 15562257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure and functional characterization of a novel human low-voltage activated calcium channel.
    Williams ME; Washburn MS; Hans M; Urrutia A; Brust PF; Prodanovich P; Harpold MM; Stauderman KA
    J Neurochem; 1999 Feb; 72(2):791-9. PubMed ID: 9930755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of T-type and L-type calcium channels by mibefradil: physiologic and pharmacologic bases of cardiovascular effects.
    Leuranguer V; Mangoni ME; Nargeot J; Richard S
    J Cardiovasc Pharmacol; 2001 Jun; 37(6):649-61. PubMed ID: 11392461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An inner pore residue (Asn406) in the Nav1.5 channel controls slow inactivation and enhances mibefradil block to T-type Ca2+ channel levels.
    McNulty MM; Kyle JW; Lipkind GM; Hanck DA
    Mol Pharmacol; 2006 Nov; 70(5):1514-23. PubMed ID: 16885209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NNC 55-0396 [(1S,2S)-2-(2-(N-[(3-benzimidazol-2-yl)propyl]-N-methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride]: a new selective inhibitor of T-type calcium channels.
    Huang L; Keyser BM; Tagmose TM; Hansen JB; Taylor JT; Zhuang H; Zhang M; Ragsdale DS; Li M
    J Pharmacol Exp Ther; 2004 Apr; 309(1):193-9. PubMed ID: 14718587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inactivation determinant in the I-II loop of the Ca2+ channel alpha1-subunit and beta-subunit interaction affect sensitivity for the phenylalkylamine (-)gallopamil.
    Sokolov S; Weiss RG; Kurka B; Gapp F; Hering S
    J Physiol; 1999 Sep; 519 Pt 2(Pt 2):315-22. PubMed ID: 10457051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological properties of Ca(V)3.2, a low voltage-activated Ca2+ channel cloned from human heart.
    Perchenet L; Bénardeau A; Ertel EA
    Naunyn Schmiedebergs Arch Pharmacol; 2000 Jun; 361(6):590-9. PubMed ID: 10882033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ca(2+)-dependent inactivation of a cloned cardiac Ca2+ channel alpha 1 subunit (alpha 1C) expressed in Xenopus oocytes.
    Neely A; Olcese R; Wei X; Birnbaumer L; Stefani E
    Biophys J; 1994 Jun; 66(6):1895-903. PubMed ID: 8075326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isoform-specific inhibition of L-type calcium channels by dihydropyridines is independent of isoform-specific gating properties.
    Hu H; Marban E
    Mol Pharmacol; 1998 May; 53(5):902-7. PubMed ID: 9584217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of 2,3-butanedione monoxime (BDM) on calcium channels expressed in Xenopus oocytes.
    Allen TJ; Mikala G; Wu X; Dolphin AC
    J Physiol; 1998 Apr; 508 ( Pt 1)(Pt 1):1-14. PubMed ID: 9490807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.